VEGFR2 (Phospho_Tyr1175) Antibody
- Known as:
- VEGFR2 (Phospho_Tyr1175) Antibody
- Catalog number:
- E011084-2
- Product Quantity:
- 100ug
- Category:
- Antibodies
- Supplier:
- EnoGene
- Gene target:
- VEGFR2 (Phospho_Tyr1175) Antibody
Related genes to: VEGFR2 (Phospho_Tyr1175) Antibody
- Gene:
- KDR NIH gene
- Name:
- kinase insert domain receptor
- Previous symbol:
- -
- Synonyms:
- FLK1, VEGFR, VEGFR2, CD309
- Chromosome:
- 4q12
- Locus Type:
- gene with protein product
- Date approved:
- 1991-07-10
- Date modifiied:
- 2019-04-23
Related products to: VEGFR2 (Phospho_Tyr1175) Antibody
Related articles to: VEGFR2 (Phospho_Tyr1175) Antibody
- Vascular endothelial growth factor (VEGF) is a key regulator of angiogenesis and an established therapeutic target in diseases such as cancer and ocular disorders. However, long-term use of most current anti-VEGF agents is often limited by their associated side effects, including hypertension, bleeding, and gastrointestinal complications. These limitations have stimulated interest in naturally occurring VEGF inhibitors derived from dietary sources, which may offer safer alternatives due to their favorable safety profiles. In this study, we investigated shared structural features of potent VEGFR2 inhibitors, focusing on naturally derived polyphenols. Polyphenols representing multiple structural subclasses were evaluated for their ability to inhibit VEGFR2 kinase activity using an in vitro kinase assay, to suppress VEGF-induced phosphorylation of VEGFR2 and downstream MAPK signaling in endothelial cells by Western blot, and to reduce VEGF-stimulated endothelial cell proliferation. Across all assays, flavonoids with strong VEGFR2 inhibitory activity displayed consistent structural characteristics, including the number and specific positioning of hydroxyl groups on the A- and B-rings, as well as specific structural elements of the C-ring. Our findings provide a strong foundation for further structure-activity relationship (SAR) studies and facilitate identification of key molecular determinants required for VEGFR2 inhibition. Elucidation of these structural patterns may contribute to the development of more effective and safer angiogenesis inhibitors with reduced adverse effects. - Source: PubMed
Publication date: 2026/04/18
Yim AndrewLu JianmingWen Wei - Follicular development in laying hens requires a balance between angiogenesis and redox status, yet their synergistic interplay across different production levels and physiological stages remains unclear. This study compared high-production (HP) and low-production (LP) hens at 50 and 75 weeks of age using morphological, antioxidant, angiogenic, and transcriptomic analyses. An acute tBHP-induced oxidative stress model was further employed to elucidate the temporal coupling between these systems. - Source: PubMed
Publication date: 2026/05/03
Qin KailongGao MingluLiu XiaoyingLiu YanliYang XiaojunYang Jiantao - Atypical fibroxanthoma (AFX) and pleomorphic dermal sarcoma (PDS) are rare cutaneous mesenchymal tumours sharing clinical and histopathological features. Compared to AFX, PDS has an increased risk of local recurrence and metastasis. A precise diagnosis is critical to ensure proper clinical management and follow-up. AFX and PDS show a similar genetic background, but also a heterogeneous pattern of different molecular abnormalities still poorly investigated due to the rarity of these tumours. Multiple data from different institutions and geographical areas, facilitate the identification of molecular alteration/s of valuable diagnostic and/or sub-classification power. We investigated the DNA profile of 32 AFX and PDS samples using a custom targeted Next-Generation Sequencing panel including 228 cancer genes. We confirm a common pattern of gene mutations affecting TP53, CDKN2A and NOTCH1. Differences appeared in less frequently detected genes (e.g. TSC2) and in NF2 harbouring novel genetic alterations. Integrating our results with published datasets of AFX and PDS mutation profiles we observed a divergent distribution of alterations in genes signalling through angiogenic pathway (KDR, PDGFRB), DNA damage response (ATR), cellular migration/metastasis (DDR2, CDH1). These differences do not reach statistical significance, and histopathological evaluation remains the diagnostic gold standard, however, they offer valuable insights into the pathogenesis of these tumours. - Source: PubMed
Publication date: 2026/05/03
Caprini ElisabettaScaglione Giovanni LucaScarponi ClaudiaMorelli MartinaMadonna StefaniaMarani CarlaSebastiani ValeriaScala EnricoAlbanesi CristinaRahimi Siavash - In this study, a novel series of chromene-based derivatives was rationally designed as potential VEGFR-2 inhibitors based on key structural and pharmacophoric features required for antiangiogenic activity. Accordingly, twelve chromene derivatives (13a-e, 15a-e, and 17a-b) were successfully synthesized and structurally characterized. The synthesized compounds were evaluated in vitro for their cytotoxic activity against human cancer cell lines (MCF-7, HepG-2, and HCT-116), in addition to normal WI-38 and WISH cells. Among the tested compounds, compound 13a demonstrated the most potent and selective antiproliferative activity, exhibiting low micromolar IC values and favorable selectivity indices. Enzymatic assays confirmed its VEGFR-2 inhibitory activity (IC = 1.666 ± 0.025 µM), comparable to the reference drug sorafenib. Mechanistic investigations revealed that compound 13a effectively inhibited cancer cell migration in a wound healing assay, highlighting its potential antiangiogenic properties. Furthermore, compound 13a induced significant G0/G1 cell cycle arrest in MCF-7 cells and triggered apoptosis, as evidenced by Annexin V/PI staining. To support the experimental findings, Density Functional Theory (DFT) calculations confirmed favorable structural stability and electronic properties. Molecular docking studies demonstrated strong binding interactions within the VEGFR-2 ATP-binding site. These results were further validated by 200 ns molecular dynamics simulations, MM-GBSA binding free energy calculations, Protein-Ligand Interaction Fingerprints (Pro-LIF), Principal Component Analysis of Trajectories (PCA-T), and Free Energy Landscape (FEL) analyses, confirming the dynamic stability and favorable energetics of the VEGFR-2-13a complex. Overall, this integrated experimental and computational study identifies compound 13a as a promising VEGFR-2-targeted anticancer lead warranting further preclinical investigation. - Source: PubMed
Elkady HazemElgammal Walid EEissa Ibrahim HMahdy Hazem AAlsfouk Aisha AAmin Fatma GHusein Dalal ZMetwaly Ahmed MElkaeed Eslam B - Angiogenesis is a fundamental prerequisite for functional tissue regeneration, and biomaterials that drive endogenous vascularization hold immense translational potential for treating tissue defects, organ damage, and ischemic diseases. Herein, gelatin methacryloyl (GelMA) and chitosan methacryloyl (CSMA) were synthesized via a copolymerization-based modification method. Hydrogel microspheres were prepared by emulsification, followed by cross-linking through photoinitiator-induced radical polymerization under UV light. Combined with freeze-drying, size-tunable porous GelMA/CSMA composite microspheres (G/CMS) were fabricated. The as-prepared G/CMS establish a favorable pro-regenerative microenvironment by integrating size-dependent mechanical feedback and charge-mediated cellular interactions. Specifically, CSMA incorporation imparted a positive surface charge, enhancing cellular affinity, while smaller diameters amplified mechanical stimuli promoting adhesion via mechanotransduction. In vitro, the optimized formulation (G/CMS-B) significantly promoted the proliferation, migration, and tube formation of human umbilical vein endothelial cells (HUVECs), and upregulated key angiogenic genes (VEGF, ANG, KDR) without exogenous growth factors. In vivo, subcutaneous implantation and hindlimb ischemia models confirmed accelerated neovascularization and blood flow recovery. The developed G/CMS exhibited excellent biocompatibility, controllable degradability, injectability, and excellent elastic recovery. This synergistic platform effectively modulates physicochemical cues to promote vascularization, offering a promising, cost-effective strategy for regenerative medicine. - Source: PubMed
Publication date: 2026/05/02
Song YuLou ZhiqiLuo ChangSong DanyangSun JiekunZhao QiuXu MiaoLiu ZiyuLiu ZhonghuaYan Tingsheng